retatrutide clinical trial stage VisualAbstract: reduces body weight by 17.5% in patients with obesity Retatrutide Shows 28% Weight Loss

In the inflammation space, Gilead is tackling chronic diseases that cause lifelong pain and disability, drastically impacting quality of life for millions of patients worldwide

Horizontal axis: Evidence strength. Vertical axis: Claim scope. Place topical skin aging and wound-care context closer to stronger evidence

For weight management or more pronounced glucose control, the dose may be gradually increased to 1.0 mg or higher over several weeks

At DFA Clinic, patients receive the best results, whether through laser skin whitening, glutathione injections, or IV cocktails

Shelf Life: 2 Years

Nature 450 , 383387 (2007) Hjorth, S